Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease
about
Intrabody and Parkinson's diseaseAssociation of Huntington's disease and schizophrenia-like psychosis in a Huntington's disease pedigree.The P42 peptide and Peptide-based therapies for Huntington's diseaseEngineering humoral immunity as prophylaxis or therapyMechanisms of RNA-induced toxicity in CAG repeat disordersIntrabodies as neuroprotective therapeuticsEngineered antibodiesElucidating a normal function of huntingtin by functional and microarray analysis of huntingtin-null mouse embryonic fibroblasts.Monoclonal antibodies recognize distinct conformational epitopes formed by polyglutamine in a mutant huntingtin fragment.Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington's disease.A protein-tagging system for signal amplification in gene expression and fluorescence imaging.Antigen-independent selection of stable intracellular single-chain antibodies.Selection and characterisation of a phage-displayed human antibody (Fab) reactive to the lung resistance-related major vault proteinEfficient isolation of soluble intracellular single-chain antibodies using the twin-arginine translocation machinery.Physico-chemical determinants of soluble intrabody expression in mammalian cell cytoplasm.An engineered viral protease exhibiting substrate specificity for a polyglutamine stretch prevents polyglutamine-induced neuronal cell death.Identification of benzothiazoles as potential polyglutamine aggregation inhibitors of Huntington's disease by using an automated filter retardation assayIsolation of a human single chain antibody fragment against oligomeric alpha-synuclein that inhibits aggregation and prevents alpha-synuclein-induced toxicityAn scFv intrabody against the nonamyloid component of alpha-synuclein reduces intracellular aggregation and toxicityDetecting morphologically distinct oligomeric forms of alpha-synuclein.Conformational targeting of fibrillar polyglutamine proteins in live cells escalates aggregation and cytotoxicity.Novel amyloid-beta specific scFv and VH antibody fragments from human and mouse phage display antibody librariesPotent inhibition of huntingtin aggregation and cytotoxicity by a disulfide bond-free single-domain intracellular antibody.Paracrine inhibition of prion propagation by anti-PrP single-chain Fv miniantibodiesEffects of intracellular expression of anti-huntingtin antibodies of various specificities on mutant huntingtin aggregation and toxicitySuppression of Huntington's disease pathology in Drosophila by human single-chain Fv antibodies.Cystamine and intrabody co-treatment confers additional benefits in a fly model of Huntington's disease.Bifunctional anti-huntingtin proteasome-directed intrabodies mediate efficient degradation of mutant huntingtin exon 1 protein fragments.Differential nuclear localization of complexes may underlie in vivo intrabody efficacy in Huntington's disease.Phage display--a powerful technique for immunotherapy: 1. Introduction and potential of therapeutic applications.Gene therapy in mouse models of huntington disease.Targeting aggregation in the development of therapeutics for the treatment of Huntington's disease and other polyglutamine repeat diseases.Expanded polyglutamine-binding peptoid as a novel therapeutic agent for treatment of Huntington's disease.The Aggregation Inhibitor Peptide QBP1 as a Therapeutic Molecule for the Polyglutamine Neurodegenerative Diseases.Huntingtin aggregation kinetics and their pathological role in a Drosophila Huntington's disease modelDevelopment of novel therapies for Huntington's disease: hope and challenge.The emerging role of the first 17 amino acids of huntingtin in Huntington's diseaseTranscriptional dysregulation of inflammatory/immune pathways after active vaccination against Huntington's diseaseBifunctional Anti-Non-Amyloid Component α-Synuclein Nanobodies Are Protective In Situ.Suppression of neuropil aggregates and neurological symptoms by an intracellular antibody implicates the cytoplasmic toxicity of mutant huntingtin
P2860
Q24653530-FBE010EA-AC13-4391-84DB-2E0D538D1ABFQ25255735-2979988A-36C1-4391-878A-88F8D560CF74Q26764930-A4C3ED84-6116-444A-B8B2-91B0679B2DD9Q26800101-2285F775-9A3C-49EB-8952-F36371FFB4AFQ26860030-9F2C971A-F375-4154-B1CA-330D69E4DF93Q27003896-044C4CEF-C79C-49D9-87E4-B4EDD8BC12CFQ28201899-26BE1DCD-2549-49E2-8476-1E0BC4CB5FDCQ30441792-1753C005-D4B0-482B-9838-895E272FCD87Q30490726-F6DF4E24-3A87-48FD-95B9-BD58E3F358EFQ30493159-A413320F-B988-4938-8B0F-9BA6AD7FBAD3Q30604320-5947B299-6E38-43E4-A832-F3474FA66E2EQ30772110-D0CCE548-34B0-4C04-8ACD-80500358627CQ30832090-A461E639-6009-4AA5-9560-D9B13E9CFC01Q30851967-1916BD98-13BA-4CD5-86AF-C4FC5BA59CCDQ30980477-F38EDBC4-C553-4288-B365-4870198FC7A3Q31028322-57574501-0C42-4494-8D19-E2CCF8A50033Q31105703-13C55B05-D58D-4713-9720-6AC97FFDE6D8Q33280345-4C38809F-77B4-42A5-9162-C5E655205426Q33317678-079B4255-5752-44A3-8CDB-9B24249D4A0BQ33399653-D0B83F2A-86B2-4D56-A6CD-0C58D1861CCBQ33459255-7198A47B-B224-4FE3-A000-5E480567EF89Q33572338-EB19D2F2-315F-4199-98EF-97A507ECC024Q33580733-3C60197D-B4BE-4B44-8DB8-4A8FE3A55713Q33843281-84EFD843-76F8-43E7-B448-42EF574B5EADQ33894812-E1D8C046-242C-492E-A51B-18E3D5FAA865Q33914222-A05B06A0-8B36-4998-87A7-C11CEBFA00C3Q34077018-24C39508-0503-418A-ACEB-E8CB47903282Q34117333-1E5837D4-E2AE-466C-8C14-9DC9805C87B7Q34313192-1A302A77-EE4D-48FD-B574-A5BD42E63D3EQ34385892-F5A57C3B-501A-4D3B-B223-D6D0FB16AA18Q35090208-42CB7DDD-B4BB-4681-BD0E-1817FA226FBEQ35095142-3C4C8D76-8DB5-4085-BEF5-40A695C6463BQ35244160-7D472F01-BB7A-425C-AA62-12D761A1F863Q35708355-866E9651-ECF0-4643-B1EF-52261929B758Q35748307-11FC3039-7E8D-4B13-A283-3637C111AA22Q36016932-EA4FBE5F-63DF-4A27-BD06-6C9BB2722124Q36110838-25CF5C22-98FA-4A42-BFAC-EB551955A795Q36142398-345D71EA-2E4B-4859-B5E8-DB646BED6D5AQ36185625-1B5C5DE4-4544-409E-9EF6-69F4D42E3FE9Q36677547-BBEC5A15-BB2C-4381-B652-78B485CD4099
P2860
Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease
description
2001 nî lūn-bûn
@nan
2001 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
name
Human single-chain Fv intrabod ...... models of Huntington's disease
@ast
Human single-chain Fv intrabod ...... models of Huntington's disease
@en
Human single-chain Fv intrabod ...... models of Huntington's disease
@nl
type
label
Human single-chain Fv intrabod ...... models of Huntington's disease
@ast
Human single-chain Fv intrabod ...... models of Huntington's disease
@en
Human single-chain Fv intrabod ...... models of Huntington's disease
@nl
prefLabel
Human single-chain Fv intrabod ...... models of Huntington's disease
@ast
Human single-chain Fv intrabod ...... models of Huntington's disease
@en
Human single-chain Fv intrabod ...... models of Huntington's disease
@nl
P2093
P2860
P3181
P356
P1476
Human single-chain Fv intrabod ...... models of Huntington's disease
@en
P2093
A Kazantsev
D E Housman
J M Lecerf
J S Huston
P Amersdorfer
T L Shirley
P2860
P304
P3181
P356
10.1073/PNAS.071058398
P407
P577
2001-04-10T00:00:00Z